dc.contributor.author | Rakıcı, Halil | |
dc.contributor.author | Akdoğan, Remzi Adnan | |
dc.contributor.author | Ayaz, Teslime | |
dc.contributor.author | Bedir, Recep | |
dc.date.accessioned | 2020-12-19T19:58:29Z | |
dc.date.available | 2020-12-19T19:58:29Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Rakici, H., Akdogan, R.A., Ayaz, T., Bedir, R. (2015). Is there any advantage of treating partners in helicobacter pylori eradication?. Gastroenterology Research and Practice, 2015. https://doi.org/10.1155/2015/706507 | |
dc.identifier.issn | 1687-6121 | |
dc.identifier.issn | 1687-630X | |
dc.identifier.uri | https://doi.org/10.1155/2015/706507 | |
dc.identifier.uri | https://hdl.handle.net/11436/2975 | |
dc.description | WOS: 000352407700001 | en_US |
dc.description | PubMed: 25861262 | en_US |
dc.description.abstract | Aim. We designed this trial to find answers to the following questions. (1) Does the success rate decrease in a country where HP prevalence is high? (2) Can we provide benefit by simultaneously treating the partners of infected patients? Materials and Methods. the first group consisted of 102 HP-positive patients, and both the patients and their HP-positive partners were treated. the second group consisted of 104 HP-positive patients whose partners were HP-positive but only the patients were treated. the participants in both groups were treated with levofloxacin 500 mg daily, amoxicillin 1 g b.i.d, and lansoprazole 30 mg b.i.d (LAL) for ten days. Results. in the per-protocol analysis, the eradication success rate was found to be 92.2% (94/8) in the first group and 90.4% (94/10) in the second group. No statistically significant difference was found between the two groups (P > 0.05). Conclusions. With regard to the HP eradication rate, no difference was found between treating the HP-positive partners of HP-positive patients simultaneously and not treating them simultaneously. According to these results, we can say that reinfections between partners do not significantly contribute to the failure of eradication. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Hindawi Ltd | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Reinfection rate | en_US |
dc.subject | Triple therapy | en_US |
dc.subject | Quadruple therapy | en_US |
dc.subject | Infection | en_US |
dc.subject | Levofloxacin | en_US |
dc.subject | Prevalence | en_US |
dc.subject | Clarithromycin | en_US |
dc.subject | Epidemiology | en_US |
dc.subject | Recurrence | en_US |
dc.title | Is there any advantage of treating partners in helicobacter pylori eradication? | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Rakıcı, Halil | |
dc.contributor.institutionauthor | Akdoğan, Remzi Adnan | |
dc.contributor.institutionauthor | Ayaz, Teslime | |
dc.contributor.institutionauthor | Bedir, Recep | |
dc.identifier.doi | 10.1155/2015/706507 | |
dc.identifier.volume | 2015 | en_US |
dc.ri.edit | oa | en_US |
dc.relation.journal | Gastroenterology Research and Practice | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |